Plain-English translation of NCT06734702 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new treatment strategy for locally advanced lung cancer that cannot be surgically removed. The trial compares two approaches that add immunotherapy and chemotherapy before radiation, versus the standard approach of radiation with chemotherapy alone. The hope is that starting with immunotherapy and chemotherapy first will help more patients respond to their treatment and live longer.
Currently, the standard treatment for this type of lung cancer is radiation combined with chemotherapy. Researchers want to see if adding immunotherapy and chemotherapy before radiation—essentially "priming" the body's immune system first—might work better than the current standard approach.
You likely qualify if…
You likely don't qualify if…
Participants will be randomly assigned to one of three groups. Some will receive immunotherapy and chemotherapy first, followed by radiation (either a faster or standard schedule) with concurrent chemotherapy, then continued immunotherapy. Others will receive the current standard treatment of radiation with chemotherapy followed by immunotherapy. The entire treatment program lasts up to 12 months, with regular clinic visits for chemotherapy infusions, radiation sessions, and immunotherapy treatments, plus blood tests and scans to monitor progress and side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China